Tempest Therapeutics Inc (NASDAQ: TPST) Is Getting Increasingly Hard To Ignore

Currently, there are 22.05M common shares owned by the public and among those 18.44M shares have been available to trade.

The company’s stock has a 5-day price change of 49.45% and 19.30% over the past three months. TPST shares are trading 23.64% year to date (YTD), with the 12-month market performance up to 132.48% higher. It has a 12-month low price of $0.17 and touched a high of $9.77 over the same period. TPST has an average intraday trading volume of 683.96K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 52.62%, 43.65%, and 105.51% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Tempest Therapeutics Inc (NASDAQ: TPST) shares accounts for 8.03% of the company’s 22.05M shares outstanding.

It has a market capitalization of $120.71M and a beta (3y monthly) value of -1.74. The earnings-per-share (ttm) stands at -$1.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.85% over the week and 11.18% over the month.

Analysts forecast that Tempest Therapeutics Inc (TPST) will achieve an EPS of -$0.37 for the current quarter, -$0.36 for the next quarter and -$1.53 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.48 while analysts give the company a high EPS estimate of -$0.33. Comparatively, EPS for the current quarter was -$0.55 a year ago. Earnings per share for the fiscal year are expected to increase by 20.37%, and -4.79% over the next financial year.

Looking at the support for the TPST, a number of firms have released research notes about the stock. Scotiabank stated their Sector Outperform rating for the stock in a research note on March 14, 2024, with the firm’s price target at $13. Jefferies coverage for the Tempest Therapeutics Inc (TPST) stock in a research note released on February 08, 2024 offered a Buy rating with a price target of $15.

Most Popular

Related Posts